Group 1 - The core proposal involves privatizing 康基医疗 (09997) through an agreement under Section 86 of the Companies Ordinance, with the offeror Knight Bidco Limited seeking to present this to shareholders [1] - Upon completion of the proposal, 康基医疗 will become a wholly-owned subsidiary of the offeror, and its shares will be delisted from the Hong Kong Stock Exchange [1] - The proposed cash consideration for shareholders is HKD 9.25 per share, representing a premium of approximately 9.9% over the last closing price of HKD 8.42 [1] Group 2 - The offeror is fully owned by MidCo, which in turn is wholly owned by TopCo, with TopCo being held by a consortium of members [1] - The consortium members hold the following approximate stakes: Fortune Spring ZM (25.53%), Fortune Spring YG (14.47%), TPG Asia VII (24.38%), Keyhole (5.01%), Knight Success (5.69%), NewQuest V (4.56%), and Al-Rayyan Holding (20.36%) [1]
康基医疗获溢价约9.9%提私有化